Critical Issues Need Answers:
Providing Best Options for Myeloma Treatment in 2013
Friday, Dec. 6, 2013
1:30pm ET/12:30pm CT/10:30am PT
Ernest N. Morial Convention Center
New Orleans, Louisiana
Click here to view the Event Slides
|Format and Topics:
The Symposium will have a unique program format that includes "Point & Counterpoint" presentations and interactive case discussions to promote audience participation.
Each point-counterpoint session will begin with an initial Clinical Question and why it is a clinical challenge followed by the presentation of 2 alternative views on the indicated issue.
Summaries of Key Relevant Data
Plus a follow up discussion open to all symposia faculty will be part of each session.
Symposium Topics Are:
- Initiate Therapy for High-Risk Smoldering Myeloma—Yes or No?
- Early Transplantation in Multiple Myeloma—Yes or No?
- Melphalan as Part of Induction Therapy for the Elderly Patient—Yes or No?
- Maintenance Therapy—Yes or No?
- Early Integration of New Therapies in the Salvage Setting—Yes or No?
Speaker 1: Brian G.M. Durie, MD
Institution: Cedars?Sinai Outpatient Cancer Center, Los Angeles, California
Speaker 2: Shaji Kumar, MD
Institution: Mayo Clinic, Rochester, MN
Speaker 3: Jesús F. San?Miguel MD, PhD
Institution: University of Salamanca, Salamanca, Spain
Speaker 4: Philippe Moreau, MD
Institution: University Hospital Hôtel?Dieu, Nantes, France
Speaker 5: Antonio Palumbo, MD
Institution: University of Turin, Turin, Italy
Speaker 6: S. Vincent Rajkumar, MD
Institution: Mayo Clinic College of Medicine, Rochester, Minnesota
- Incorporate new data and/or ongoing clinical trials into the management algorithm for patients with high-risk smoldering multiple myeloma
- Choose optimal primary induction therapy for patients with multiple myeloma in both the transplantation-eligible and transplantation-ineligible settings
- Plan optimal maintenance therapy approaches for patients with multiple myeloma
- Choose optimal therapy for patients with relapsed/refractory multiple myeloma by applying current guideline recommendations and data on emerging therapeutic options
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.
The Annenberg Center for Health Sciences at Eisenhower designates this live activity for a maximum of 4.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflicts of Interest
The Annenberg Center for Health Sciences at Eisenhower (Annenberg Center) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
This activity is supported by educational grants from: AMGEN, Celgene Corporation, Millennium: The Takeda Oncology Company, ONYX Pharmaceuticals and The Binding Site.